Dr. Yongping Wang is the director of the Cell Based Therapy Lab (CBTL) at the Children's Hospital of Philadelphia and an associate professor of Clinical Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine. He has been at the CBTL for 12 years.

The CBTL is a current Good Manufacturing Practice facility accredited by the Foundation for the Accreditation of Cellular Therapy and the College of American Pathologists. It processes and manufactures cell and gene therapy (CGT) products for bone marrow transplant and other CGT patients at CHOP. These range from standard-of-care, to investigational (IND/IDE), to commercially available CGT products.

CBTL is currently involved in more than 50 trials that cover transplant graft manipulation, virus specific T cells, chimeric antigen T (CAR-T) cells, and gene therapy for hemoglobinopathies. Sponsors for these trials include internal CHOP investigators, outside academic institutions, and industrial/commercial collaborators. With its partners at Penn, CHOP was the main clinical site that conducted the trials leading to the FDA approval of Kymriah. CHOP has infused more than 500 unique CAR-T patients.

BS, Yale University, New Haven, CT

MD, PhD, Dartmouth Medical School, Hanover, NH

Chief Resident, University of Pennsylvania, Philadelphia (Clinical Pathology)

Fellowship, University of Pennsylvania, Philadelphia (Transfusion Medicine)

Postdoctoral Fellow, University of Pennsylvania, Philadelphia

Certificate, American College of Pathology (Clinical Pathology and Transfusion Medicine)

Director of the Cell Based Therapy Laboratory at CHOP

Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine

International Society for Cell and Gene Therapy

Association for the Advancement of Blood and Biotherapies

Cell Based Therapy Laboratory